miR-223 promotes colon cancer by directly targeting p120 catenin

Liu, Liwei; Zhang, Chao; Li, Xiyu; Sun, Wenjia; Qin, Shenghui; Qin, Lingzhi; Wang, Xi

doi:10.18632/oncotarget.19541

Cited by 23 publications

(20 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…highlightedmiR-223 as a tumor inhibitor in breast cancer [14], Eto et al have reportedmiR-223 inhibits gastric cancer progression [15], and Dong et al have shown that miR-223 is used to control the increase of cell death rate to control the increase of liver cancer cells [18]. Furthermore, several researches have found that miR-223 repression colon cancer progression [19][20][21].In the latest research, we observed decreased act of miR-223 in 38 paired PTC tissue specimens. We also studied the relationship between miR-223 and clinical pathological parameters of PTC, and found that there is a certain relationship between lower miR-223 level and late TNM stage and cervical metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MiR-223 down-regulates RHOB to inhibit progression of papillary thyroid cancer

Zhang¹,

Ji²,

Zhao³

2019

Preprint

View full text Add to dashboard Cite

Backgrounds The incidence of thyroid carcinoma continues to increase every year. The incidence of papillary thyroid carcinoma (PTC) is the largest of all thyroid cancers, and is the most widely seen.Thus, Do some identification and testing of biomarkers related to tumorigenesis and development, which will help understand and treat PTC.Methods The expression of miR-223 and RHOB needs to be detected by polymerase chain reaction and western blot, respectively. Thyroid cell-line BCPAP and K1 cells were cultured, transfected for overexpression of miR-223or RHOB, and evaluated using MTT, Transwell, and apoptosis assays. In order to better understand the relationship between miR-223 and RHOB, dual luciferase reporter gene detection and RHOB rescue experiments were performed. In addition, clinical pathological parameters and correlation analysis of patients with miR-223 were also performed.Results Aberrant expression of miR-223 was detected in PTC samples. We also determined that miR-223 expression was associated with TNM staging and cervical metastasis. Moreover, miR-223 inhibits the increase in cell number and position, as well as defense against cancer cells and accelerates cell death. Furthermore, miR-223 excessive expression was associated with a significant inhibition of RHOB levels. According to the luciferase test report, it can be known miR-223 was able to bind RHOB 3′-UTR, it is possible to change its stability through these, and finally achieve the purpose of reducing RHOB. Finally,excessive expression of RHOB has undergone earth-shaking changes in the effect of miR-223 overexpression on cell number growth, invasion and disappearance.Conclusion Aberrant miR-223/RHOB expression took part in PTC make headway and miR-223 inhibition caused RHOB overexpression and cancer progression. Therefore, miR-223 may be a potential therapeutic target for PTC. BackgroundThe incidence of thyroid cancer has also become higher and higher, but the incidence of thyroid papillary cancer (PTC) has been ranked first [1]. In addition, the fifth most common tumor in women is PTC [2, 3]. The biological behavior of different PTCs varies widely. Some exhibit few clinical symptoms while others are aggressive and may be fatal. This phenomenon is associated with different genetic of cancer epidemiology 2013, 2013:965212. 4. Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B et al: Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. The Journal of clinical investigation 2016, 126(3):1052-1066. 5. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ: Processing of primary microRNAs by the Microprocessor complex. Nature 2004, 432(7014):231-235. 6. Mo YY: MicroRNA regulatory networks and human disease. Cellular and molecular life sciences : CMLS 2012, 69(21):3529-3531. 7. Risueno A, Sarasquete ME, Ferminan E, Fisac R et al: Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14. PloS one 2012...

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, miR-223 phenotypes have been reported in both hematological malignancies [8][9][10][11][12] and in solid tumors, such as breast cancer [13,14], gastric cancer [15,16], hepatic cancer [17,18], and colon cancer [19][20][21]. However, what kind of function does miR-223 have in PTC?…”

Section: Introductionmentioning

confidence: 99%

MiR-223 down-regulates RHOB to inhibit progression of papillary thyroid cancer

Zhang¹,

Ji²,

Zhao³

2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Also, Liu et al showed miR‐223 expression was remarkably increased in colon cancer tissues and inversely correlated with p120 expression. miR‐223 overexpression increased c‐Myc, cyclinD1, MMP7 protein levels which are related to cell proliferation and invasion, suggesting miR‐223 played an oncogenic role in colon cancer . In non‐small cell lung cancer (NSCLC), high miR‐223 expression was observed in sputum or blood samples of NSCLC patients, and ROC curve analysis revealed serum miR‐223 had high predictive accuracy in early‐stage NSCLC detection .…”

Section: Discussionmentioning

confidence: 99%

“…miR-223 overexpression increased c-Myc, cyclinD1, MMP7 protein levels which are related to cell proliferation and invasion, suggesting miR-223 played an oncogenic role in colon cancer. 29 In non-small cell lung cancer (NSCLC), high miR-223 expression was observed in sputum or blood samples of NSCLC patients, and ROC curve analysis revealed serum miR-223 had high predictive accuracy in early-stage NSCLC detection. 30,31 The role of miR-223 in human tumorigenesis seemed to be a doubleedged sword and its function might depend on tumor progression.…”

Section: Discussionmentioning

confidence: 99%

Low serum miR‐223 expression predicts poor outcome in patients with acute myeloid leukemia

Yin

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Identification of biomarkers for acute myeloid leukemia (AML) is important for treating this malignancy. Recent studies have reported that microRNAs (miRNAs) are stably detectable in the blood/plasma and can be used as biomarkers for various types of cancer including AML. The aim of this study was to analyze miR‐223 level in serum as a potential indicator for AML diagnosis and prognosis prediction. Methods Quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR) was used to detect the levels of miR‐223 in the serum samples from 131 patients and 70 healthy individuals. Results The results revealed that serum miR‐223 was underexpressed in AML patients, particularly those in intermediate and unfavorable cytogenetic risk groups. Further analysis revealed that serum miR‐223 could yield a receiver operating characteristic (ROC) area under the curve (AUC) of 0.849 with 83.2% sensitivity and 81.4% specificity. Moreover, a significant increase in serum miR‐223 level was observed in AML subjects after their treatment. Reduced serum miR‐223 level was highly associated with aggressive clinical variables and shorter survival of patients. Furthermore, miR‐223 expression was identified to be an independent prognostic predictor of worse overall survival. Conclusion In conclusion, miR‐223 may be a reliable diagnostic and prognostic biomarker for AML.

show abstract

“…In developed countries, such as the United States, about 50 000 deaths appeared every year . Due to recurrence and localized or distant metastases, most patients with colorectal cancer had very poor prognosis and short survival time . At present, many progresses have been made in screening tests and targeted therapeutics for colorectal cancer, which was helpful to reduce mortality.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA 32 promotes cell proliferation, migration, and suppresses apoptosis in colon cancer cells by targeting OTU domain containing 3

Jin

Cheng

Cao

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Colorectal cancer is considered as the fourth leading reason of cancer‐linked deaths worldwide. However, our knowledge about its pathogenic mechanism remains inadequate. MicroRNA 32 (miR‐32), a member of small noncoding RNAs, has been found vital roles in tumorigenesis. This study studied its functions and underlying mechanism in colorectal cancer. The experiment revealed the obvious upregulation of miR‐32 in colorectal cancer tissues and six cancer cell lines, compared with normal tissues and cells. Moreover, miR‐32 upregulation reduced cell apoptosis and promoted cell proliferation and migration, while its downregulation displayed opposite effects. Dual luciferase reporter assays proved that miR‐32 bound to the 3′‐untranslated region (3′‐UTR) of OTU domain containing 3 (OTUD3), suggesting that miR‐32 directly targeted OTUD3. Further experiments demonstrated that overexpression of miR‐32 could reduce the expression level of OTUD3. Furthermore, OTUD3 silence promoted proliferation and motility and decreased apoptosis for HCT116 cells and restored partly miR‐32‐mediated cell proliferation, migration, and antiapoptosis for colon cancer. Therefore, our study indicated that miR‐32 enhanced cell proliferation and motility abilities, and inhibited apoptosis by directly targeting OTUD3 in colon cancer cells, which implied that miR‐32 was hopeful to be a biomarker or target used for diagnosis and therapy of colon cancer.

show abstract

miR-223 promotes colon cancer by directly targeting p120 catenin

Cited by 23 publications

References 43 publications

MiR-223 down-regulates RHOB to inhibit progression of papillary thyroid cancer

MiR-223 down-regulates RHOB to inhibit progression of papillary thyroid cancer

Low serum miR‐223 expression predicts poor outcome in patients with acute myeloid leukemia

MicroRNA 32 promotes cell proliferation, migration, and suppresses apoptosis in colon cancer cells by targeting OTU domain containing 3

Contact Info

Product

Resources

About